Meta Drug & Pharmaceutical Ads Policy 2026 — Prescription Rules, OTC Advertising & Pharmacy Authorization

Meta Drug & Pharmaceutical Policy Scope

Meta's Restricted Drugs and Pharmaceuticals policy covers any product that falls under healthcare or drug regulatory oversight in any major market where Meta serves ads. The policy applies to prescription drug advertising, over-the-counter medication advertising, online pharmacies, telehealth platforms, medical devices, compounded pharmaceuticals, and a range of adjacent categories where regulator attention has intensified in recent years.

The policy exists because pharmaceutical advertising creates elevated consumer safety risk, faces rigorous jurisdiction-specific regulation, and has historically been one of the most heavily enforced restricted categories across digital platforms. By gating pharmaceutical advertising behind category authorization and targeting restrictions, Meta creates an accountability structure that aligns platform enforcement with the underlying regulatory landscape.

Meta's advertising standards generally allow prescription drug ads only with prior written permission and in certain countries, and require online pharmacies to be certified and to serve only jurisdictions where they hold appropriate dispensing authorization (see Meta's Drugs and Pharmaceuticals policy for current wording).
— AuditSocials Policy Analysis Team

Prescription Drug DTC Advertising Rules

Direct-to-consumer prescription drug advertising is permitted on Meta only in jurisdictions where DTC prescription advertising is legal under local pharmaceutical regulation. The principal permitted markets are the United States and New Zealand, where DTC advertising is established practice. Most other jurisdictions prohibit or severely restrict DTC prescription advertising, and Meta enforces the restriction at the audience targeting level.

Key DTC Rules in Permitted Markets

• Authorization required: Advertisers must complete Meta's drug and pharmaceutical authorization before ads can run.
• Fair balance: Efficacy claims must be balanced by appropriate risk information presented with comparable prominence.
• Brand and generic consistency: Both brand name and generic name must appear; the indication must match the approved label.
• Approved indication only: Off-label promotion is prohibited; creative must reference only approved indications.
• Risk presentation: Material risks must be disclosed with prominence comparable to efficacy claims.
• Adequate provision: On digital platforms, adequate provision for full prescribing information is typically satisfied through a link to the full labeling.
• No promotion of withdrawn or warning-letter products: Products under FDA enforcement or withdrawn from market cannot be advertised.

For a complete breakdown of US pharmaceutical advertising compliance, see our US Meta Compliance Guide.

OTC Medication Advertising Rules

Over-the-counter medication advertising is permitted in most major markets, but each jurisdiction applies category-specific rules that Meta enforces through a combination of automated review and manual verification.

OTC categories that face additional scrutiny include pain relief products (restrictions on efficacy comparisons), allergy and respiratory products (requirements around sponsored claims), and smoking cessation products (additional disclosure and age targeting).

Online Pharmacy & Telehealth Authorization

Online pharmacies and telehealth platforms face dedicated authorization requirements because they combine dispensing and prescribing activities with cross-border reach. Meta's authorization process for these advertisers is the most rigorous in the pharmaceutical category.

Online Pharmacy Authorization Steps

• Dispensing license verification: Advertiser submits dispensing license documentation for each jurisdiction it serves.
• Certification program evidence: Where applicable, evidence of accreditation under a recognized program (such as the US Digital Pharmacy Accreditation) or listing on a national register.
• Cross-border operations review: Meta reviews any cross-border dispensing activity against source and destination jurisdiction rules.
• Product catalog review: Advertisers disclose product categories offered and demonstrate authorization for controlled substances, prescription drugs, and OTC products separately.
• Landing page audit: Destination pages are reviewed for regulatory status display, verification emblems, and compliant purchase flows.

Telehealth Platform Rules

• Consultation-only platforms face lighter restrictions than platforms that prescribe medication.
• Platforms that prescribe controlled substances face additional restrictions and often require managed-account relationships.
• Weight loss-focused telehealth platforms face category-specific scrutiny around compounded medication access.
• Creative cannot imply guaranteed prescription outcomes from a consultation.

For a full healthcare advertising framework, see our Healthcare Social Media Compliance guide.

Weight Loss & Compounded Medication Enforcement

The weight loss category has been the most dynamic subcategory in Meta's drug and pharmaceutical policy through 2025 and into 2026, driven by consumer demand for GLP-1 medications, rapid growth in telehealth-compounder partnerships, and regulatory enforcement actions against aspects of the compounded supply chain.

Current Policy Posture

• FDA-approved branded GLP-1 products can be advertised under the standard prescription drug DTC framework in permitted jurisdictions, subject to fair balance and risk disclosure.
• Compounded GLP-1 medications face prohibition in most advertising contexts, reflecting regulatory concerns about the compounded supply chain.
• Supplement-style weight loss products marketed without FDA approval face blanket prohibition on Meta when they make weight loss efficacy claims.
• Telehealth platforms offering weight loss consultations must specify the regulatory pathway of any mentioned product and cannot imply guaranteed access to compounded formulations.

Enforcement in this subcategory is among the most active in Meta's restricted categories, with automated detection trained specifically on weight loss creative patterns. Advertisers in the weight loss space should expect elevated review times and build regulatory review buffers into launch schedules.

Disclosure Framework by Jurisdiction

• United States (FDA): Fair balance; brand and generic name; approved indication; major risks; adequate provision for full prescribing information.
• European Union: DTC prescription prohibited broadly; OTC requires risk warnings and advice to consult a healthcare professional.
• United Kingdom: MHRA marketing authorization reference; ABPI Code compliance for prescribing-influencing content.
• Canada: Name, indication, and risk information; adequate provision rules for digital platforms.
• Australia (TGA): Therapeutic Goods Advertising Code compliance; restricted representation rules; prohibition on certain claims without regulator approval.

Disclosure sufficiency is the advertiser's responsibility. Meta's ad review verifies presence of required elements but does not certify that disclosures meet local regulatory standards. Parallel regulatory review should be conducted for every pharmaceutical creative before submission.

Pharmaceutical Advertiser Compliance Checklist

• [ ] Drug and pharmaceutical category authorization obtained
• [ ] License or marketing authorization documented for each target jurisdiction
• [ ] Product category mapping (Rx, OTC, device, compounded, supplement) completed
• [ ] Targeting restricted to authorized jurisdictions
• [ ] Creative includes fair balance (for Rx in permitted markets)
• [ ] Brand and generic names consistent with approved label
• [ ] Only approved indication referenced; no off-label promotion
• [ ] Risk information presented with appropriate prominence
• [ ] Adequate provision for full prescribing information (via link to labeling page)
• [ ] Landing page includes required disclosures and regulatory status
• [ ] Online pharmacy accreditation displayed where applicable
• [ ] Weight loss creative reviewed against compounded-medication restrictions
• [ ] Parallel regulatory review of creative completed
• [ ] Rejection response protocol documented

Monitor Meta's pharmaceutical policy evolution via our Policy Change Tracker.